Semaglutide may reduce Alzheimer's risk in type 2 diabetes patients, with research suggesting significant protective benefits compared to other diabetes drugs. Researchers at School of Medicine have ...
Semaglutide, the active ingredient in Ozempic and Wegovy, may lower the risk of Alzheimer’s disease.A new study suggests type 2 diabetes patients taking semaglu ...
There is a potential breakthrough for patients who could be in danger of losing their vision. A first-of-its-kind treatment is now being used in Massachusetts. Kevin Ratcliffe is a glaucoma patient at ...